Promising Oral Medication for Treating Fatal Childhood Brain Disease
A new oral drug, leriglitazone, shows early promise in reversing or halting the progression of fatal childhood brain disease cALD, offering hope for safer, more accessible treatment options.
A groundbreaking international research effort has identified a promising new oral drug that could significantly alter the treatment landscape for cerebral adrenoleukodystrophy (cALD), a rare and often fatal genetic disorder affecting young boys between the ages of 3 and 12. The investigational drug, leriglitazone, is currently being evaluated in the NEXUS trial, a multi-phase clinical study conducted across the United States, Europe, and South America. Recent analysis after six months involving 11 participants revealed that leriglitazone slowed the progression of disease symptoms in all patients, with nearly half of the boys showing no further signs of advancement—indicating a potential to halt the disease altogether. This early positive outcome suggests a breakthrough in treatment options for cALD, which until now has been limited to high-risk procedures like stem cell transplants and gene therapy, both carrying significant risks and accessibility issues.
Dr. Eric Mallack, the senior author of the study and Director of Clinical Research at the Moser Center for Leukodystrophies at Kennedy Krieger Institute, emphasized the significance of these findings. "This is the first indication that an oral medication could slow or stop this devastating disease," he stated. Dr. Mallack and his team contributed extensively to the study design, MRI assessments, and data analysis, leveraging years of expertise in MRI and disease natural history.
If approved, leriglitazone would become the first oral drug approved for cALD, potentially offering a safer and more accessible treatment for affected children. The study's results have been published in the journal eClinicalMedicine, marking a hopeful stride toward more effective management of this aggressive neurological disorder.
For more details, see the original publication: Ángeles García-Cazorla et al, "Safety and efficacy of leriglitazone in childhood cerebral adrenoleukodystrophy (NEXUS): an interim analysis of an open-label, phase 2/3 trial" in eClinicalMedicine (2025).
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Why ChatGPT Can't Replace Medical Diagnoses: Key Insights
Expert insights reveal that while ChatGPT can assist with medical information, it is not equipped to diagnose health conditions accurately, emphasizing the importance of consulting healthcare professionals.
New Biomarker Could Optimize KRAS Inhibitor Use in Lung Cancer Treatment
A new biomarker called TTF-1 has been identified to predict patient response to KRAS inhibitors in lung cancer, enabling personalized treatment strategies and improving outcomes for advanced NSCLC with KRAS G12C mutations.
Innovative Skin Stretching Technique Enables Needle-Free Vaccine Delivery in Mice
Skin stretching activates immune cells and enhances permeability, enabling effective needle-free vaccine delivery in mice—a promising development for non-invasive immunization methods.
Breakthrough AI Model Attains High Precision in Liver Tumor Segmentation
A novel AI model developed by researchers in Tokyo achieves high-accuracy liver tumor segmentation from CT scans using minimal data, surpassing traditional models and enabling broader clinical application.